Patent Case Watch

Patent opinions from the Eastern District of Texas and the U.S. Court of Appeals for the Federal Circuit

Fed. Cir.

Nuvo Pharmaceuticals v. Dr. Reddy's Laboratories Inc., No. 17-2487 (Fed. Cir. Aug. 7, 2019)

Reversed
Written Description Invalidity (§ 102/§ 103)
Court
U.S. Court of Appeals for the Federal Circuit
Case No.
No. 17-2487
Also Docketed
No. 17-2488 (consolidated; same document)
Decided
August 7, 2019
Judge
Per curiam
Document
Nonprecedential Opinion
Length
3 pages

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Lupin Ltd. (Appeal No. 2017-2487) and Lupin Pharma- ceuticals, Inc. (Appeal No. 2017-2488) appeal from the final judgment of t he United States District Court for the Dis- trict of New Jersey. Horizon Pharma, Inc. v. Lupin Ltd. , No. 3:11-cv-04275-MCL-DEA (D.N.J. July 21, 2017) (final judgment). That final judgment sustained the validity of U.S. Patent Nos. 6,926,907 (“the ’907 pat ent”) and 8,557,285 (“the ’285 patent”), and found the appellants in- fringed those patents.

Download Opinion (PDF)

Source: govinfo.gov USCOURTS collection · retrieved July 23, 2026 · Report an error